Skip to main content
Premium Trial:

Request an Annual Quote

He's Baaaaaack ... Or Not

UPDATE: The Boston Globe's Carolyn Johnson reports that embattled researcher Marc Hauser will not be teaching at Harvard next spring, despite reports to the contrary. "He will not be teaching; he will not be in the classroom at Harvard next year," says Susan Carey, the chairwoman of Harvard's psychology department. "A large majority of the members of the department of psychology voted in February to not offer courses taught by Professor Hauser during the 2011-2012 academic year," says Harvard spokesman Jeff Neal. Neal adds the Harvard Crimson was incorrect when it reported that Hauser would be back and teaching two courses next spring. It is still unclear what Hauser's role will be at the university next fall, Johnson says, and the sanctions taken against him by Harvard for misconduct remain undisclosed.

Once esteemed by colleagues and students alike, Harvard researcher Marc Hauser's star came crashing to earth last August after it was discovered that he may have fabricated data in some of his most well-known studies, and that the university was investigating his lab for misconduct. A few days later, Harvard found Hauser solely responsible for eight counts of misconduct, and although the consequences to Hauser were kept confidential, he went on leave and classes he had been planning to teach were cancelled, reports Heidi Ledford at Nature's Great Beyond blog. In an exclusive statement to the New York Times last August, Hauser expressed a wish to go back to teaching and research. Now, Ledford says, he has gotten his wish, and will be teaching two courses next spring, "Psychology 1066: 'Origins of Evil' and Psychology 2381: 'Hot Topics in Cognitive Science and Neuroscience'." Additionally, his lab at Harvard remains open, but the Harvard Crimson reports it is under additional oversight by the university.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.